Invo BioScience (INVO)
(Delayed Data from NSDQ)
$0.84 USD
+0.02 (2.18%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Invo BioScience Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 1 | 4 | 1 | 1 |
Cost Of Goods | 2 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 4 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 8 | 11 | 9 | 6 | 3 |
Income After Depreciation & Amortization | -7 | -11 | -5 | -6 | -2 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 1 | 0 | 1 | 3 | 0 |
Pretax Income | -8 | -11 | -7 | -8 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -11 | -7 | -8 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -11 | -7 | -8 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -10 | -4 | -3 | -1 |
Depreciation & Amortization (Cash Flow) | 1 | 0 | 1 | 3 | 0 |
Income After Depreciation & Amortization | -7 | -11 | -5 | -6 | -2 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.57 | 0.61 | 0.53 | 0.28 | 0.24 |
Diluted EPS Before Non-Recurring Items | -5.13 | -18.00 | -12.60 | -30.40 | -6.40 |
Diluted Net EPS (GAAP) | -5.13 | -18.00 | -12.60 | -30.40 | -6.40 |
Fiscal Year end for Invo BioScience Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.84 | 1.58 | 1.38 | 0.97 | 0.32 |
Cost Of Goods | 1.09 | 1.08 | 1.21 | 0.60 | 0.26 |
Gross Profit | 0.74 | 0.50 | 0.18 | 0.37 | 0.06 |
SG&A, R&D, and Dept/Amort Expenses | 2.65 | 1.44 | 1.69 | 1.26 | 2.12 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.91 | -0.94 | -1.51 | -0.89 | -2.06 |
Non-Operating Income | 0.03 | -0.47 | -0.28 | -0.01 | 0.00 |
Interest Expense | 0.37 | 0.18 | 0.18 | 0.35 | 0.18 |
Pretax Income | -2.25 | -1.59 | -1.97 | -1.25 | -2.24 |
Income Taxes | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.25 | -1.60 | -1.99 | -1.25 | -2.24 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.25 | -1.60 | -1.99 | -1.25 | -2.24 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.61 | 3.80 | NA | 1.78 | 0.73 |
Diluted EPS Before Non-Recurring Items | -0.62 | -0.42 | NA | -0.70 | -3.06 |
Diluted Net EPS (GAAP) | -0.62 | -0.42 | 2.63 | -0.70 | -3.06 |